**Proteins** 

# PKR activator 3

Cat. No.: HY-19702 CAS No.: 1628428-01-2 Molecular Formula:  $C_{24}H_{28}N_4O_4S$ 

Molecular Weight: 468.57

Target: Pyruvate Kinase

Pathway: Metabolic Enzyme/Protease

Storage: Powder -20°C 3 years

> 4°C 2 years

In solvent -80°C 2 years

> -20°C 1 year

**Product** Data Sheet

### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 50 mg/mL (106.71 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.1342 mL	10.6708 mL	21.3415 mL
	5 mM	0.4268 mL	2.1342 mL	4.2683 mL
	10 mM	0.2134 mL	1.0671 mL	2.1342 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.34 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- $\beta$ -CD in saline) Solubility: ≥ 2.5 mg/mL (5.34 mM); Clear solution

## **BIOLOGICAL ACTIVITY**

Description	PKR activator 3 is a pyruvate kinase isoform PKR activator extracted from patent WO2014139144A1, compound 160. PKR activator 3 can be used for the research of PKR function related diseases, including cancer, diabetes, obesity, autoimmune disorders, and benign prostatic hyperplasia <sup>[1]</sup> .
IC <sub>50</sub> & Target	$PKR^{[1]}$

### **REFERENCES**

1]. Popovici-Muller, et al. Preparation of N-(piperidinecarbonylphenyl) sulfonamide compounds as pyruvate kinase modulators. From PCT Int. Appl. (2014), WO2014139144A1 20140918.						
			dical applications. For research use on			
	Tel: 609-228-6898	Fax: 609-228-5909 1 Deer Park Dr, Suite Q, Monmo	E-mail: tech@MedChemExpress.co	om		
	Addi C33.	i beer rank bi, baite Q, Moiiino	atti saitetioti, NS 00032, OSA			

Page 2 of 2 www.MedChemExpress.com